Novartis AG agreed to acquire Ziarco Group Ltd., a privately held company focused on developments of novel treatments in dermatology, for an undisclosed sum.

The acquisition will add a once-daily oral H4 receptor antagonist in development for eczema to Novartis' dermatology portfolio and pipeline.

The transaction is subject to customary closing conditions, including regulatory approval.